Axon Therapies Secures $32 Million in Series A Funding
Axon Therapies, an innovative medical device company focused on heart failure treatment, has successfully raised $32 million in an oversubscribed Series A funding round. This significant financing is set to propel clinical trials for a minimally invasive therapy targeting the underlying causes of heart failure. With fresh leadership under co-founder Zoar Engelman, PhD, who now serves as CEO, the company is poised to enhance its development efforts.
Advancing Heart Failure Treatments
The primary goal of this funding is to fast-track Axon Therapies' ongoing clinical development efforts. Specifically, it will support two double-blinded randomized feasibility studies focusing on heart failure, a critical health issue that affects millions globally. These studies will include a confirmatory trial for a groundbreaking splanchnic ablation therapy in patients diagnosed with Heart Failure with Preserved Ejection Fraction (HFpEF) and a multi-center study for those with Heart Failure with Reduced Ejection Fraction (HFrEF).
Significant Clinical Development
This crucial funding allows Axon Therapies to continue its pioneering work in heart failure treatment. Dr. Engelman has emphasized the urgency and need for effective treatments in this area, stating, "Heart failure is one of the leading causes of hospitalization and death worldwide, yet patients still face a lack of effective treatment options." This investment will enable the company to advance into pivotal trials, reflecting a commitment to providing much-needed solutions to patients.
Innovative Therapy Approach
Axon’s proprietary approach, known as Splanchnic Ablation for Volume Management (SAVM), targets the overactive sympathetic nervous system, which plays a significant role in heart failure progression. Their Satera™ Ablation System is a catheter-based, implant-free procedure designed to improve patient quality of life and slow disease advancement.
International Expansion of Operations
In conjunction with the new funding, Axon Therapies has launched its European headquarters, Axon Vascular Europe Ltd, located in the UK. This strategic move aims to create a dedicated hub for accelerating clinical trial initiatives and prepares the company for a significant entry into the European heart failure market. Dr. Engelman remarked on the importance of this new office in advancing their mission and expanding their reach.
Importance of This Funding Round
The support from investment partners, including Earlybird Venture Capital and Santé Ventures, underscores the confidence in Axon’s vision. Dr. Yianni, a Partner at Earlybird, noted the critical need for solutions that address heart failure effectively, while Dr. Eadie from Santé Ventures highlighted Axon's potential to capture a significant share of a multi-billion-dollar market. The research conducted through these feasibility studies is expected to reduce risks and provide a solid foundation for upcoming pivotal trials.
Heart Failure – A Global Health Challenge
Heart failure continues to pose a significant public health challenge, impacting over 64 million individuals worldwide and leading to more than 1 million annual hospitalizations in the United States alone. Despite advancements in pharmaceutical and device therapies, many patients remain symptomatic and lack sufficient treatment options.
About Axon Therapies
Founded by the MedTech incubator Coridea, Axon Therapies is a groundbreaking company dedicated to developing minimally invasive techniques to tackle the root causes of heart failure. The company aims to enhance patient care and quality of life through its innovative therapies, including the Satera™ Ablation System, which seeks to improve outcomes without necessitating surgical implants. By engaging with respected healthcare investors, Axon is well-positioned to change the landscape of heart failure treatments.
Frequently Asked Questions
What is the focus of Axon Therapies?
Axon Therapies is dedicated to developing minimally invasive therapies targeting the root causes of heart failure.
How much funding did Axon Therapies raise?
The company raised $32 million in an oversubscribed Series A funding round.
Who is the CEO of Axon Therapies?
Zoar Engelman, PhD, co-founder of the company, has been appointed as the CEO.
What is the Satera™ Ablation System?
The Satera™ Ablation System is a catheter-based, implant-free procedure aimed at treating heart failure.
Where is Axon Therapies' European headquarters located?
The new headquarters is established in the UK, aiming to enhance their clinical trial capacities in Europe.
